Annual report pursuant to Section 13 and 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Development Award and Deferred Revenue (Details Narrative)

v3.8.0.1

Development Award and Deferred Revenue (Details Narrative)				1 Months Ended			3 Months Ended								12 Months Ended
	Jan. 31, 2017 USD ($)	Aug. 31, 2016 USD ($)	Apr. 20, 2015 USD ($) Installments	Nov. 30, 2017 USD ($)	Nov. 30, 2015 USD ($)	May 31, 2015 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)
Development Award [Line Items]
Revenue								$ 796,312	$ 350,186	$ 1,293,697	$ 375,670	$ 742,558	$ 396,598	$ 396,598	$ 2,440,195	$ 1,911,424	$ 648,382
2015 CFFT Award Agreement [Member]
Development Award [Line Items]
Amount received upon execution of award agreement	$ 1,000,000	$ 1,000,000		$ 500,000	$ 1,250,000	$ 1,250,000
2015 CFFT Award Agreement [Member] \| Oral Anti-inflammatory Drug [Member]
Development Award [Line Items]
Amount received upon execution of award agreement			$ 5,000,000
2015 CFFT Award Agreement [Member] \| Lenabasum [Member]
Development Award [Line Items]
Number of installments \| Installments			3
Payment due period after the first commercial sale			90 days
Royalty payment, sales target			$ 500,000,000
2015 CFFT Award Agreement [Member] \| Lenabasum [Member] \| Upon Transfer Sale or Licensing [Member]
Development Award [Line Items]
Royalty payable			15,000,000
2015 CFFT Award Agreement [Member] \| Maximum [Member]
Development Award [Line Items]
Development award received			5,000,000
2015 CFFT Award Agreement [Member] \| Maximum [Member] \| Lenabasum [Member] \| Upon Commercialization of The Product [Member]
Development Award [Line Items]
Royalty payable			25,000,000
2015 CFFT Award Agreement [Member] \| Maximum [Member] \| Lenabasum [Member] \| Upon Reaching The Sales Target [Member]
Development Award [Line Items]
Royalty payable			$ 5,000,000

- Definition

Development Award [Line Items]

+ References

No definition available.

+ Details

Name:	CRBP_DevelopmentAwardLineItems
Namespace Prefix:	CRBP_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of installments.

+ References

No definition available.

+ Details

Name:	CRBP_NumberOfInstallments
Namespace Prefix:	CRBP_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Payment due period after the first commercial sale.

+ References

No definition available.

+ Details

Name:	CRBP_PaymentDuePeriodAfterTheFirstCommercialSale
Namespace Prefix:	CRBP_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty payment sales target.

+ References

No definition available.

+ Details

Name:	CRBP_RoyaltyPaymentSalesTarget
Namespace Prefix:	CRBP_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355

+ Details

Name:	us-gaap_GainContingencyUnrecordedAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_OralAntiinflammatoryDrugMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_LenabasumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=CRBP_UponTransferSaleOrLicensingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=CRBP_UponCommercializationOfTheProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=CRBP_UponReachingTheSalesTargetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: